FDA OKs Voluven for post-op blood loss

Dec 28, 2007

The U.S. Food and Drug Administration has approved Voluven as a treatment for blood loss after surgery.

Voluven is an intravenous solution that expands blood volume, the agency said Thursday in a release.

Significant blood loss can cause a rapid drop in the volume of red blood cells and plasma circulating through the body. This can lead to shock, which is potentially fatal.

Blood volume expanders are commonly administered to restore quickly some of the lost volume so remaining red blood cells can continue to deliver needed oxygen to the body's tissues, the FDA said.

Voluven, made by the German-firm Fresenius Kabi, contains a synthetic starch that does not dissolve in water. It was found in clinical trials to be as safe and effective as other blood volume expanders, the agency said.

The most common side effects from Voluven were nausea and itching.

Copyright 2007 by United Press International

Explore further: Italy bans Novartis flu vaccine after suspicious deaths

add to favorites email to friend print save as pdf

Related Stories

US northeast braces for flooding after record snow

2 hours ago

Weather forecasters and emergency officials warned Sunday that melting snow would lead to heavy flooding in parts of the US northeast, with hundreds of thousands of people told to brace for fast-rising waters.

How the hummingbird achieves its aerobatic feats

9 hours ago

(Phys.org) —The sight of a tiny hummingbird hovering in front of a flower and then darting to another with lightning speed amazes and delights. But it also leaves watchers with a persistent question: How ...

'Mind the gap' between atomically thin materials

10 hours ago

In subway stations around London, the warning to "Mind the Gap" helps commuters keep from stepping into empty space as they leave the train. When it comes to engineering single-layer atomic structures, minding ...

Recommended for you

Have a cold? Don't ask your doctor for antibiotics

Nov 26, 2014

Antibiotic resistance is a major threat to public health. Resistance makes it harder for physicians to treat infections and can increase the chance patients will die from an infection. What is more, the treatment ...

Powdered measles vaccine found safe in early clinical trials

Nov 25, 2014

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.